HUP0200852A2 - Combinations of formoterol and fluticasone propionate for asthma - Google Patents

Combinations of formoterol and fluticasone propionate for asthma

Info

Publication number
HUP0200852A2
HUP0200852A2 HU0200852A HUP0200852A HUP0200852A2 HU P0200852 A2 HUP0200852 A2 HU P0200852A2 HU 0200852 A HU0200852 A HU 0200852A HU P0200852 A HUP0200852 A HU P0200852A HU P0200852 A2 HUP0200852 A2 HU P0200852A2
Authority
HU
Hungary
Prior art keywords
formoterol
asthma
combinations
fluticasone propionate
fluticasone
Prior art date
Application number
HU0200852A
Other languages
English (en)
Inventor
Jeremy Guy Clarke
Henry Luke Danahay
Ian Francis Hassan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10848051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0200852(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0200852A2 publication Critical patent/HUP0200852A2/hu
Publication of HUP0200852A3 publication Critical patent/HUP0200852A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0200852A 1999-02-18 2000-02-16 Combinations of formoterol and fluticasone propionate for asthma HUP0200852A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9903759.0A GB9903759D0 (en) 1999-02-18 1999-02-18 Organic compounds

Publications (2)

Publication Number Publication Date
HUP0200852A2 true HUP0200852A2 (en) 2002-08-28
HUP0200852A3 HUP0200852A3 (en) 2004-04-28

Family

ID=10848051

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200852A HUP0200852A3 (en) 1999-02-18 2000-02-16 Combinations of formoterol and fluticasone propionate for asthma

Country Status (32)

Country Link
US (4) US20020103260A1 (hu)
EP (1) EP1152753B1 (hu)
JP (1) JP2002537249A (hu)
KR (2) KR20070104955A (hu)
CN (1) CN1339965A (hu)
AR (1) AR022609A1 (hu)
AT (1) ATE266393T1 (hu)
AU (1) AU758999B2 (hu)
BR (1) BR0008276A (hu)
CA (1) CA2368537A1 (hu)
CO (1) CO5140098A1 (hu)
CZ (1) CZ20012976A3 (hu)
DE (1) DE60010662T2 (hu)
DK (1) DK1152753T3 (hu)
ES (1) ES2220411T3 (hu)
GB (1) GB9903759D0 (hu)
HK (1) HK1042429A1 (hu)
HU (1) HUP0200852A3 (hu)
ID (1) ID29437A (hu)
IL (1) IL144061A (hu)
MY (1) MY126768A (hu)
NO (1) NO20013987D0 (hu)
NZ (1) NZ513526A (hu)
PE (1) PE20001545A1 (hu)
PL (1) PL349856A1 (hu)
PT (1) PT1152753E (hu)
RU (1) RU2249454C2 (hu)
SK (1) SK11842001A3 (hu)
TR (1) TR200102110T2 (hu)
TW (1) TWI229601B (hu)
WO (1) WO2000048587A1 (hu)
ZA (1) ZA200105391B (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
EP1143930B8 (en) 1999-09-11 2008-03-19 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
GB2385596B (en) * 1999-09-11 2004-03-03 Glaxo Group Ltd Container for pharmaceutical formulation of fluticasone propionate
GB2392915B (en) * 1999-09-11 2004-04-28 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
US20030026766A1 (en) * 2000-04-13 2003-02-06 Mark Sanders Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0009591D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
MXPA03007017A (es) * 2001-02-06 2004-09-13 Innovata Biomed Ltd Medicamentos.
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
AU2002234476B2 (en) * 2001-03-30 2006-04-27 Jagotec Ag Medical aerosol formulations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
ATE396716T1 (de) † 2002-02-04 2008-06-15 Glaxo Group Ltd Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1599209B1 (en) 2002-08-21 2011-08-17 Norton Healthcare Limited Inhalation composition
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527069C2 (sv) * 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
WO2008137446A1 (en) * 2007-05-03 2008-11-13 Trustees Of Boston University Methods and compositions for the treatment of respiratory disease
LT2435025T (lt) 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Veikliosios medžiagos tiekimas per kvėpavimo takus
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
WO2011093811A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical preparations comprising formoterol and fluticasone
KR20180028563A (ko) * 2010-10-12 2018-03-16 시플라 리미티드 약학 조성물
AU2011368334A1 (en) * 2011-05-17 2013-11-21 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
RU2678992C2 (ru) * 2012-04-11 2019-02-05 Сипла Лимитед Фармацевтическая композиция, содержащая арформотерол и флутиказона фуроат
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
DE69232462T2 (de) * 1991-12-18 2002-10-10 Astrazeneca Ab, Soedertaelje Formoterol und budesonide enthaltende zusammensetzung
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
ATE284677T1 (de) * 1997-03-20 2005-01-15 Schering Corp Herstellung von pulveragglomeraten

Also Published As

Publication number Publication date
EP1152753B1 (en) 2004-05-12
IL144061A0 (en) 2002-04-21
DE60010662D1 (de) 2004-06-17
KR20010102205A (ko) 2001-11-15
HK1042429A1 (en) 2002-08-16
US20020103260A1 (en) 2002-08-01
AR022609A1 (es) 2002-09-04
NO20013987L (no) 2001-08-16
MY126768A (en) 2006-10-31
AU758999B2 (en) 2003-04-03
GB9903759D0 (en) 1999-04-14
EP1152753A1 (en) 2001-11-14
NZ513526A (en) 2004-01-30
US20100034890A1 (en) 2010-02-11
PL349856A1 (en) 2002-09-23
US20050287079A1 (en) 2005-12-29
ZA200105391B (en) 2002-06-21
TR200102110T2 (tr) 2001-10-22
US20040101487A1 (en) 2004-05-27
WO2000048587A1 (en) 2000-08-24
CO5140098A1 (es) 2002-03-22
CZ20012976A3 (cs) 2001-11-14
JP2002537249A (ja) 2002-11-05
HUP0200852A3 (en) 2004-04-28
ES2220411T3 (es) 2004-12-16
CA2368537A1 (en) 2000-08-24
CN1339965A (zh) 2002-03-13
AU2911500A (en) 2000-09-04
SK11842001A3 (sk) 2001-12-03
KR20070104955A (ko) 2007-10-29
PT1152753E (pt) 2004-09-30
RU2249454C2 (ru) 2005-04-10
TWI229601B (en) 2005-03-21
ID29437A (id) 2001-08-30
ATE266393T1 (de) 2004-05-15
NO20013987D0 (no) 2001-08-16
PE20001545A1 (es) 2001-01-29
BR0008276A (pt) 2001-11-06
DK1152753T3 (da) 2004-08-16
DE60010662T2 (de) 2005-05-19
IL144061A (en) 2005-12-18

Similar Documents

Publication Publication Date Title
PL349856A1 (en) Combinations of formoterol and fluticasone propionate for asthma
HUP0200142A2 (en) Combinations of formoterol and mometasone furoate for asthma
HUP0103108A3 (en) Use of composition comprising formoterol and budesonide for the prevention of an acute condition of asthma
IL134773A0 (en) New use for budesonide and formoterol
HUP0200014A3 (en) Pharmaceutical aerosol compositions containing fluoroalkanes, budesonide and formoterol
AU4672301A (en) Medical combinations comprising formoterol and fluticasone proprionate
AU4671601A (en) Medical combinations comprising formoterol and budesonide
HUP0201872A3 (en) Steroid compounds and pharmaceutical compositions of the same
PL358375A1 (en) Medicaments for treating respiratory disorders comprising formoterol and fluticasone
PL365582A1 (en) Use of salmeterol and fluticasone propionate combination
AU3065999A (en) Compositions and methods for treatment of asthma
AU2002237400A1 (en) Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
SI1152753T1 (en) Combinations of formoterol and fluticasone propionate for asthma
HK1044468A1 (zh) 治療哮喘和炎症的小肽和方法
GB2392915B (en) Pharmaceutical formulation of fluticasone propionate
HU9802379D0 (en) Inhaler for treatment of asthma
SI1156790T1 (en) Combinations of formoterol and mometasone furoate
SI1085877T1 (sl) Uporaba sestavka, ki obsega formoterol in budezonid, za preprečevanje ali zdravljenje akutnega stanja
GB0312326D0 (en) Pharmaceutical formulation of fluticasone propionate

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished